Sai Life Sciences DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025


0.75×	0.75×	0.75×
1.00×	1.00×	0.85×
21.5%	21.2%	15.8%
0.65×	0.65×	0.54×
1.46×	1.46×	1.48×
15.3%	15.1%	8.0%
15.1%	15.1%	8.0%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SAILIFE₹1,495.70

Sai Life Sciences Ltd.

· Pharma & Health

₹ CrorePeersSYNGENE DIVISLAB PPLPHARMA NH NEULANDLAB NATCOPHARM LALPATHLAB COHANCEMcap ₹31,676 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.75	0.75	0.75
Interest Burden (Pretax/EBIT) ×	0.85	1.00	1.00
EBIT Margin %	15.76	21.18	21.47
Asset Turnover ×	0.54	0.65	0.65
Financial Leverage (Assets/Equity) ×	1.48	1.46	1.46
ROE (5-step product, year-end total equity) %	8.05	15.10	15.25
ROE (owners' profit / average owners' equity) %	7.99	15.13	15.13

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.